OncoMatch/Clinical Trials/NCT06592326
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Is NCT06592326 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including 9MW2821 and Toripalimab for urothelial carcinoma.
Treatment: 9MW2821 · Toripalimab · Gemcitabine · Cisplatin/Carboplatin — This is a randomized, controlled, open-label, multicenter phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of 9MW2821 combined with Toripalimab versus standard chemotherapy in first-line locally advanced or metastatic urothelial cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or CTLA-4 inhibitor
Previously treated with PD-1, PD-L1, PD-L2, CTLA-4 inhibitors
Cannot have received: antibody-drug conjugate
Exception: ADCs which target Nectin-4 or are conjugated with payload MMAE
Previously treated with ADCs which target Nectin-4 or are conjugated with payload MMAE
Cannot have received: radiation therapy
Exception: within 21 days
Radiotherapy or Intravesical therapy treated within 21 days
Cannot have received: major surgery
Exception: within 28 days
Major surgery treated within 28 days
Cannot have received: live vaccine
Exception: within 28 days
Any live vaccines got within 28 days
Cannot have received: traditional Chinese medicine
Exception: within 14 days
Traditional Chinese medicine or any potent CYP3A4 inducers/inhibitors taken within 14 days
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ functions.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify